UNSPSC 51262006: Carvedilol phosphate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C24H26N2O4.H2O.2H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EQT531S367, chemically known as 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino), phosphate (salt), hydrate (2:2:1), but more generally known as carvedilol phosphate, which bears US NIH Compound Identifier 11954344.

UNSPSC 51262006 Carvedilol phosphate is a Commodity code nominally identifying a specific cardiovascular pharmaceutical product, but recent state and local procurement activity under this code does not align with its intended scope. The two recent opportunities posted show no actual carvedilol procurement; instead, Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB, and the Texas Health and Human Services Commission issued an RFI exploring direct-to-manufacturer pharmacy prescription models. Neither opportunity targets carvedilol or matches the code's pharmaceutical ingredient classification. State and local procurement offices appear to have tagged these health-related acquisitions with an incorrect UNSPSC code, suggesting either data-entry error or a mismatch between the code's nominal scope and how jurisdictions classify pharmaceutical and pharmacy-benefit-management activity in practice.

Geographically, the limited recent activity under this code spans Florida and Texas. The Seminole County naloxone IFB, posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Texas HHS Commission RFI, posted April 3, 2026, with the same response date, sought vendor capabilities for direct pharmaceutical contracting outside traditional pharmacy benefit manager arrangements. The code shows minimal relevant recent activity aligned with its pharmaceutical product definition; business development professionals evaluating this code should verify correct UNSPSC classification before committing resources to pursuit under 51262006.